Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-22

Veracyte (VCYT)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,421,877
Marc Stapley total, FY2025
32nd
CEO pay percentile vs peers
38:1
CEO-to-median pay ratio
97.4%
Say-on-pay support, latest vote
Companies that benchmark against VCYT
17 companies name VCYT as a compensation peer

Each company listed discloses VCYT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VCYT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Marc Stapley$700,000$0$5,890,877$0$826,000$0$5,000$7,421,877
Chief Executive Officer
John Leite510,30002,356,3250331,18505,0003,202,810
Global Chief Commercial Officer
Rebecca Chambers550,00001,963,6040356,95005,0002,875,554
Chief Financial Officer
Annie McGuire500,00001,963,6040324,50005,0002,793,104
General Counsel and Head of Market Access
Phillip Febbo561,00001,570,8830364,08905,0002,500,972
Chief Scientific Officer and Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Marc Stapley$7,421,877$6,816,368$7,184,634+605,509
John Leite3,202,8103,093,9511,924,469+108,859
Rebecca Chambers2,875,5543,645,3462,778,584−769,792
Annie McGuire2,793,1043,090,8482,481,118−297,744
Phillip Febbo2,500,9722,789,6613,787,041−288,689

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Annie McGuireSVP, General Counsel2026-05-06D5,102$40$204,080CommonForm 4 ↗
Annie McGuireSVP, General Counsel2026-05-06D5,10238194,131CommonForm 4 ↗
Robert S. EpsteinDirector2026-05-20D10,00044440,129CommonForm 4 ↗
Jonathan WygantVP, Chief Accounting Officer2026-05-22D24,000451,089,624CommonForm 4 ↗
Jonathan WygantVP, Chief Accounting Officer2026-05-22A24,00025595,200CommonForm 4 ↗
Jonathan WygantVP, Chief Accounting Officer2026-05-22D24,00000Derivative, Class A CommonForm 4 ↗
John LeiteGlobal Chief Commercial Off2026-06-02D4,05948194,020CommonForm 4 ↗
Rebecca ChambersChief Financial Officer2026-06-02D1,6004978,854CommonForm 4 ↗
Marc StapleyDirector2026-06-02D138,051506,919,585CommonForm 4 ↗
John LeiteGlobal Chief Commercial Off2026-06-02D13,97550699,732CommonForm 4 ↗
Rebecca ChambersChief Financial Officer2026-06-02D1,9615098,229CommonForm 4 ↗
Annie McGuireEVP, General Counsel2026-06-02D3,29248157,358CommonForm 4 ↗
Annie McGuireEVP, General Counsel2026-06-02D1,7765089,007CommonForm 4 ↗
Jonathan WygantVP, Chief Accounting Officer2026-06-02D1,3614865,056CommonForm 4 ↗
Rebecca ChambersChief Financial Officer2026-06-02D3,69348176,525CommonForm 4 ↗
Phillip FebboChief Scientific & Med Officer2026-06-02D3,73048178,294CommonForm 4 ↗
Marc StapleyDirector2026-06-02A138,051375,052,667CommonForm 4 ↗
Marc StapleyDirector2026-06-02D138,05100Derivative, Class A CommonForm 4 ↗
Marc StapleyDirector2026-06-02D9,01248430,774CommonForm 4 ↗
Annie McGuireEVP, General Counsel2026-06-02D1,4004969,029CommonForm 4 ↗
Robert S. EpsteinDirector2026-06-11A5,27200CommonForm 4 ↗
Jens HolsteinDirector2026-06-11A5,27200CommonForm 4 ↗
Muna BhanjiDirector2026-06-11A5,27200CommonForm 4 ↗
Tom MillerDirector2026-06-11A5,27200CommonForm 4 ↗
Brent ShaferDirector2026-06-11A5,27200CommonForm 4 ↗
Karin EasthamDirector2026-06-11A5,27200CommonForm 4 ↗
Eliav BarrDirector2026-06-11A5,27200CommonForm 4 ↗
Evan JonesDirector2026-06-11A5,27200CommonForm 4 ↗
Karin EasthamDirector2026-06-18D5295428,328CommonForm 4 ↗
Karin EasthamDirector2026-06-18D3,20053168,906CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Annie McGuireRSU2025-03-0630,200$981,802
Marc StapleyPSU2025-03-0661,15690,601135,9022,945,439
Phillip FebboRSU2025-03-0624,160785,442
John LeitePSU2025-03-0624,46236,24054,3601,178,162
Marc StapleyRSU2025-03-0690,6012,945,439
Phillip FebboPSU2025-03-0616,30824,16036,240785,442
Annie McGuirePSU2025-03-0620,38530,20045,300981,802
Rebecca ChambersRSU2025-03-0630,200981,802
Rebecca ChambersPSU2025-03-0620,38530,20045,300981,802
John LeiteRSU2025-03-0636,2401,178,162
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Annie McGuire$981,802$981,802$050.0%
Marc Stapley2,945,4392,945,439050.0%
Phillip Febbo785,442785,442050.0%
John Leite1,178,1621,178,162050.0%
Rebecca Chambers981,802981,802050.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
John LeiteRSU17,221$725,004
Marc StapleyRSU3,534148,781
John LeiteRSU36,2401,525,704
Annie McGuirePSU22,446944,977
Phillip FebboOption39,35221.96
Annie McGuireRSU57,9852,441,169
Phillip FebboRSU46,3881,952,935
Annie McGuireRSU1,42960,161
John LeiteOption7,89723.73
Marc StapleyRSU133,3685,614,793
John LeiteRSU57,9852,441,169
Marc StapleyPSU51,6262,173,455
Rebecca ChambersRSU31,5411,327,876
Rebecca ChambersRSU30,2001,271,420
Annie McGuirePSU30,2001,271,420
Annie McGuireRSU28,3881,195,135
Rebecca ChambersPSU26,9361,134,006
Rebecca ChambersPSU22,650953,565
John LeitePSU22,446944,977
Rebecca ChambersOption13,42423.73
Annie McGuireOption12,08223.73
John LeiteRSU4,928207,469
Rebecca ChambersOption2,36126.02
Marc StapleyRSU90,6013,814,302
Marc StapleyPSU90,6013,814,302
Phillip FebboRSU24,1601,017,136
Annie McGuireRSU30,2001,271,420
Phillip FebboPSU24,1601,017,136
Marc StapleyRSU94,6283,983,839
Marc StapleyOption40,27223.73
Rebecca ChambersRSU69,5812,929,360
Rebecca ChambersRSU1,29654,562
Phillip FebboRSU74,4553,134,556
John LeiteOption8,07119.81
Marc StapleyOption6,44026.02
Annie McGuireOption1,75827.8
Phillip FebboPSU17,957755,990
John LeitePSU36,2401,525,704
John LeiteRSU4,819202,880
05

Incentive-plan design — the Compensation Discussion & Analysis

We have designed our executive compensation program to reward our executive officers, including our NEOs, at a level consistent with our overall strategic and financial performance and to provide remuneration sufficient to attract, retain and motivate them to exert their best efforts in the highly competitive environment in which we operate.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1071,266,7711,858,80543,63497.4%Passed
20252025-06-1767,829,4701,849,21111,54597.33%Passed
20242024-06-1264,610,0973,179,57854,52695.23%Passed
20222022-06-1559,077,7315,356,35219,68191.66%Passed
20212021-06-0755,705,7744,601,09769,69792.26%Passed
20202020-06-0539,733,1341,228,494337,29196.21%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1097.4%a
20252025-06-1797.33%b
20242024-06-1295.23%c

a. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "AGAINST" this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "AGAINST" this proposal.”.

c. Approved under the standard stated in the filing — “3, the approval, on a non-binding advisory basis, of the compensation of our named executive officers, you may vote "FOR," vote "AGAINST" or "ABSTAIN." Abstentions have the same effect as votes "AGAINST" this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)38 : 1
CEO total compensation$7,421,877
Median employee compensation$196,646
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Robert S. EpsteinIndependent · Board Chair · Nominating and Corporate Governance (Chair)$110,000$249,989$0$0$359,989
Jens HolsteinIndependent · Audit (Chair) · Compensation77,500249,98900327,489
Evan JonesIndependent · Regulatory and Compliance (Chair) · Audit · Nominating and Corporate Governance75,000249,98900324,989
Karin EasthamIndependent · Compensation (Chair) · Audit75,000249,98900324,989
Muna BhanjiIndependent · Nominating and Corporate Governance · Regulatory and Compliance60,000249,98900309,989
Brent ShaferIndependent · Compensation57,500249,98900307,489
Tom MillerIndependent · Regulatory and Compliance55,000249,98900304,989
Eliav BarrIndependent · Regulatory and Compliance55,000249,98900304,989
Marc StapleyEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$249,989
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 7,500 / 5,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$565,000
Equity awards (grant-date value)$1,999,912
All other compensation$0
Total cost of the board$2,564,912

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Veracyte names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Veracyte.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exact Sciences2024Kevin Conroy$1,083,368$13,496,138$0$712,329$15,539,378
2Natera2025Steven Chapman853,71012,979,55801,114,15114,957,319
3Twist Bioscience2025Emily Leproust720,00011,998,1340932,91813,781,570
4BioCryst Pharmaceuticals2025Jon Stonehouse728,466011,132,4581,052,63312,951,082
5Glaukos2025Thomas Burns850,0007,649,9473,527,497012,034,087
6Nevro2023Kevin Thornal515,62510,080,1730402,75011,453,548
7Ultragenyx Pharmaceutical2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
8Vericel2025Dominick Colangelo860,0003,964,6305,456,287860,00011,156,368
9Maravai Lifesciences2025Bernd Brust388,8637,660,0001,460,000425,34310,129,708
10NeoGenomics2025Tony Zook601,5393,999,9973,998,235513,4009,127,092
11Adaptive Biotechnologies2025Chad Robins698,2587,675,1000703,3809,081,690
12Guardant Health2025AmirAli Talasaz18,647,709008,661,227
13Amicus Therapeutics2024Bradley Campbell767,3084,990,3652,105,62708,526,943
14Veracyte2025Marc Stapley700,0005,890,8770826,0007,421,877
15CareDX2025John Hanna693,2695,622,6380852,5157,179,699
1610x Genomics2025Serge Saxonov674,2505,020,2690634,7256,329,244
17Fulgent Genetics2025Ming Hsieh1,000,0004,000,00001,207,0006,207,000
18Myriad Genetics2025Samraat Raha856,9013,989,7290814,6605,686,740
19Cytek Biosciences2025Wenbin Jiang620,0002,000,0002,000,000485,2115,120,061
20Pacific Biosciences of California2025Christian Henry748,2501,151,0131,696,278714,3054,309,846

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Veracyte118%PSU 50 · RSU 50NoAon
10x Genomics93%PSU 60 · RSU 40Yes — 3-year Relative TSRAlpine Rewards LLC
Adaptive Biotechnologies100%RSU 50 · PSU 50NoSemler Brossy Consulting Group, LLC
Amicus Therapeutics108%Options 33 · RSU 33 · PSU 33Yes — TSR GoalPay Governance
BioCryst Pharmaceuticals170%not disclosednot disclosedAon Human Capital Solutions (division of Aon plc)
CareDX122%RSU 70 · PSU 30NoAlpine Rewards
Cytek Biosciences78.4%RSU 50 · Options 50not disclosedMeridian Compensation Partners, LLC
Exact Sciences47%PSU 60 · RSU 40NoAon
Fulgent Genetics120.7%PSU 60 · RSU 40NoUSI
Glaukos177.5%PSU 50NoFrederic W. Cook & Co., Inc.
Guardant Health140%PSU 50 · RSU 50NoAon
Maravai Lifesciencesnot disclosednot disclosedNoMeridian Compensation Partners, LLC
Myriad Genetics89%RSU 50 · PSU 50YesMercer
Natera131.1%PSU 50 · RSU 50NoAon
NeoGenomics60%RSU 50 · Options 50not disclosedWTW
Nevro53.7%RSU 50 · PSU 50NoAon
Pacific Biosciences of California95%not disclosednot disclosedAon Human Capital Solutions
Twist Bioscience129.6%PSU 50 · RSU 50Nonot disclosed
Ultragenyx Pharmaceutical44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice
Vericel100%Options 58 · RSU 42not disclosedFW Cook

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Marc StapleyDEF 14A2026-04-220001384101-26-000021Section “Summary Compensation Table”. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422
2Section 01, John LeiteDEF 14A2026-04-220001384101-26-000021Section “Summary Compensation Table”. As printed: 3,202,810. Filing ↗machine: r13 · c27 · span 873667–873676
3Section 01, Rebecca ChambersDEF 14A2026-04-220001384101-26-000021Section “Summary Compensation Table”. As printed: 2,875,554. Filing ↗machine: r7 · c27 · span 861491–861500
4Section 01, Annie McGuireDEF 14A2026-04-220001384101-26-000021Section “Summary Compensation Table”. As printed: 2,793,104. Filing ↗machine: r16 · c27 · span 879786–879795
5Section 01, Phillip FebboDEF 14A2026-04-220001384101-26-000021Section “Summary Compensation Table”. As printed: 2,500,972. Filing ↗machine: r10 · c27 · span 867589–867598
6Section 03, Annie McGuire RSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r19 · c14 · span 947918–947925
7Section 03, Marc Stapley PSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r7 · c14 · span 906305–906314
8Section 03, Phillip Febbo RSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r13 · c14 · span 927099–927106
9Section 03, John Leite PSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r16 · c14 · span 937489–937498
10Section 03, Marc Stapley RSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r7 · c14 · span 906305–906314
11Section 03, Phillip Febbo PSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r13 · c14 · span 927099–927106
12Section 03, Annie McGuire PSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r19 · c14 · span 947918–947925
13Section 03, Rebecca Chambers RSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r10 · c14 · span 916706–916713
14Section 03, Rebecca Chambers PSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r10 · c14 · span 916706–916713
15Section 03, John Leite RSUDEF 14A2026-04-220001384101-26-000021Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r16 · c14 · span 937489–937498
16Section 07, pay ratioDEF 14A2026-04-220001384101-26-000021Section “CEO Pay Ratio”. As printed: 38 : 1. Filing ↗machine: span 1198160–1198162
17Section 08, Robert S. EpsteinDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 359,989. Filing ↗machine: t74 · r7 · c6 · span 360640–360647
18Section 08, Jens HolsteinDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 327,489. Filing ↗machine: t74 · r8 · c6 · span 362119–362126
19Section 08, Evan JonesDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 324,989. Filing ↗machine: t74 · r9 · c6 · span 363595–363602
20Section 08, Karin EasthamDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 324,989. Filing ↗machine: t74 · r6 · c6 · span 359156–359163
21Section 08, Muna BhanjiDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 309,989. Filing ↗machine: t74 · r5 · c6 · span 357677–357684
22Section 08, Brent ShaferDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 307,489. Filing ↗machine: t74 · r11 · c6 · span 366773–366780
23Section 08, Tom MillerDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 304,989. Filing ↗machine: t74 · r10 · c6 · span 365071–365078
24Section 08, Eliav BarrDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 304,989. Filing ↗machine: t74 · r4 · c6 · span 356204–356211
25Section 08, Marc StapleyDEF 14A2026-04-220001384101-26-000021Section “Director Compensation”. As printed: 0. Filing ↗
26Section 02, Annie McGuire 2026-05-06Form 42026-05-080001914620-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Annie McGuire 2026-05-06Form 42026-05-080001914620-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Robert S. Epstein 2026-05-20Form 42026-05-220001252004-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Jonathan Wygant 2026-05-22Form 42026-05-270001584145-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Jonathan Wygant 2026-05-22Form 42026-05-270001584145-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Jonathan Wygant 2026-05-22Form 42026-05-270001584145-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, John Leite 2026-06-02Form 42026-06-040001991536-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Rebecca Chambers 2026-06-02Form 42026-06-040001823563-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Marc Stapley 2026-06-02Form 42026-06-040001539796-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, John Leite 2026-06-02Form 42026-06-040001991536-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Rebecca Chambers 2026-06-02Form 42026-06-040001823563-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Annie McGuire 2026-06-02Form 42026-06-040001914620-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Annie McGuire 2026-06-02Form 42026-06-040001914620-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Jonathan Wygant 2026-06-02Form 42026-06-040001584145-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Rebecca Chambers 2026-06-02Form 42026-06-040001823563-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Phillip Febbo 2026-06-02Form 42026-06-040001649245-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Marc Stapley 2026-06-02Form 42026-06-040001539796-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Marc Stapley 2026-06-02Form 42026-06-040001539796-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Marc Stapley 2026-06-02Form 42026-06-040001539796-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Annie McGuire 2026-06-02Form 42026-06-040001914620-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Robert S. Epstein 2026-06-11Form 42026-06-150001252004-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jens Holstein 2026-06-11Form 42026-06-150001819880-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Muna Bhanji 2026-06-11Form 42026-06-150001846905-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Tom Miller 2026-06-11Form 42026-06-150002034921-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Brent Shafer 2026-06-11Form 42026-06-150001728374-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Karin Eastham 2026-06-11Form 42026-06-150001231845-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Eliav Barr 2026-06-11Form 42026-06-150001940521-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Evan Jones 2026-06-11Form 42026-06-150001020741-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Karin Eastham 2026-06-18Form 42026-06-220001231845-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Karin Eastham 2026-06-18Form 42026-06-220001231845-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
56Section 06, 2026 voteForm 8-K2026-06-110001384101-26-000038Item 5.07 · say-on-pay result. As reported: 97.4% (votes for as printed: 71,266,771). Filing ↗
57Section 06, 2025 voteForm 8-K2025-06-180001384101-25-000083Item 5.07 · say-on-pay result. As reported: 97.33% (votes for as printed: 67,829,470). Filing ↗
58Section 06, 2024 voteForm 8-K2024-06-130001384101-24-000093Item 5.07 · say-on-pay result. As reported: 95.23% (votes for as printed: 64,610,097). Filing ↗
59Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
60Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
61Section 09b board cost (computed)ComputedcomputedCash 565,000 + equity 1,999,912 + all other 0 = 2,564,912, summed across the director compensation table rows.machine: formula: Σ = 2,564,912
62Exact Sciences, Section 10b CEO totalDEF 14A2025-04-290001124140-25-000034CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865
63Natera, Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
64Twist Bioscience, Section 10b CEO totalDEF 14A2026-01-060001581280-26-000006CEO total compensation as printed in Twist Bioscience's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961
65BioCryst Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
66Glaukos, Section 10b CEO totalDEF 14A2026-04-160001193125-26-157829CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. Filing ↗machine: t93 · r6 · c38 · span 1876942–1876952
67Nevro, Section 10b CEO totalDEF 14A2024-04-120000950170-24-044100CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993
68Ultragenyx Pharmaceutical, Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
69Vericel, Section 10b CEO totalDEF 14A2026-03-190001308179-26-000094CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754
70Maravai Lifesciences, Section 10b CEO totalDEF 14A2026-04-240001823239-26-000014CEO total compensation as printed in Maravai Lifesciences's own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655
71NeoGenomics, Section 10b CEO totalDEF 14A2026-04-060001077183-26-000014CEO total compensation as printed in NeoGenomics's own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469
72Adaptive Biotechnologies, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177409CEO total compensation as printed in Adaptive Biotechnologies's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717
73Guardant Health, Section 10b CEO totalDEF 14A2026-04-280001193125-26-187403CEO total compensation as printed in Guardant Health's own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158
74Amicus Therapeutics, Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137
75Veracyte (subject), Section 10b CEO totalDEF 14A2026-04-220001384101-26-000021CEO total compensation as printed in Veracyte's own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422
76CareDX, Section 10b CEO totalDEF 14A2026-04-270001217234-26-000028CEO total compensation as printed in CareDX's own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661
7710x Genomics, Section 10b CEO totalDEF 14A2026-04-240001628280-26-027201CEO total compensation as printed in 10x Genomics's own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292
78Fulgent Genetics, Section 10b CEO totalDEF 14A2026-03-310001674930-26-000020CEO total compensation as printed in Fulgent Genetics's own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288
79Myriad Genetics, Section 10b CEO totalDEF 14A2026-04-140000899923-26-000031CEO total compensation as printed in Myriad Genetics's own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792987–792997
80Cytek Biosciences, Section 10b CEO totalDEF 14A2026-04-280001140361-26-017479CEO total compensation as printed in Cytek Biosciences's own proxy. As printed: 5,120,061. Filing ↗machine: r2 · c21 · span 561243–561252
81Pacific Biosciences of California, Section 10b CEO totalDEF 14A2026-04-230001299130-26-000064CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983
82Section 10a, 10x Genomics reciprocityDEF 14A0001628280-26-02720110x Genomics names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
83Section 10a, Exact Sciences reciprocityDEF 14A0001124140-25-000034Exact Sciences's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
84Section 10a, Maravai Lifesciences reciprocityDEF 14A0001823239-26-000014Maravai Lifesciences names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
85Section 10a, Natera reciprocityDEF 14A0001104659-26-047770Natera's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
86Section 10a, Guardant Health reciprocityDEF 14A0001193125-26-187403Guardant Health's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
87Section 10a, Glaukos reciprocityDEF 14A0001193125-26-157829Glaukos's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
88Section 10a, Amicus Therapeutics reciprocityDEF 14A0001140361-25-015479Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
89Section 10a, Fulgent Genetics reciprocityDEF 14A0001674930-26-000020Fulgent Genetics names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
90Section 10a, Vericel reciprocityDEF 14A0001308179-26-000094Vericel's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
91Section 10a, Adaptive Biotechnologies reciprocityDEF 14A0001193125-26-177409Adaptive Biotechnologies names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
92Section 10a, CareDX reciprocityDEF 14A0001217234-26-000028CareDX names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
93Section 10a, Cytek Biosciences reciprocityDEF 14A0001140361-26-017479Cytek Biosciences names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
94Section 10a, BioCryst Pharmaceuticals reciprocityDEF 14A0001628280-26-026822BioCryst Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
95Section 10a, Ultragenyx Pharmaceutical reciprocityDEF 14A0001308179-26-000174Ultragenyx Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
96Section 10a, Nevro reciprocityDEF 14A0000950170-24-044100Nevro's most recent proxy was read; its disclosed peer group does not include Veracyte. Filing ↗
97Section 10a, NeoGenomics reciprocityDEF 14A0001077183-26-000014NeoGenomics names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗
98Section 10a, Pacific Biosciences of California reciprocityDEF 14A0001299130-26-000064Pacific Biosciences of California names Veracyte in its own disclosed peer group (read from its most recent proxy). Filing ↗